Dr. Hanns Lochmüller Recipient of the Dr. George Karpati Award for Researcher of the Year

The NMD4C are excited to share that the network’s lead investigator Dr. Hanns Lochmüller is the recipient of Muscular Dystrophy Canada’s Dr. George Karpati Award for Researcher of the Year! This prestigious award is presented annually to an exemplary neuromuscular clinician or researcher who has made a significant contribution to neuromuscular research, or the advancement of care of people with neuromuscular disorders. 

Dr. Lochmuller is a neurologist and clinical academic specializing in genetic neuromuscular disorders and rare disease in Ottawa, and supports the neuromuscular community in many ways: He is the lead Principal Investigator of the Neuromuscular Disease Network for Canada (NMD4C); He is an active member of MDC’s Medical and Scientific Advisory Committee (MSAC); He reviews research grants, speaks at various webinars, contributes to publications (over 30 in 2021 alone!), serves as a role model for early career clinicians and scientists, as well as serving as an academic lead on MDC’s Economic Cost of Living Study.

Dr. Lochmuller is a champion for the patient community and is strongly committed to bringing patients and patient organizations into equal partnerships. He has been instrumental in ensuring individuals impacted by NMDs and their family members are at the center of advances in the neuromuscular community in Canada and abroad.

Read more about Dr. Lochmüller’s accomplishments and research here, or visit the Lochmüller Lab website.

Hanns_KarpatiAward

Read next...

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.

Website - SBMA published on CMAJ.png

New Best Practice Recommendations for SBMA Care in Canada

Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!

2025 NMD4C ANNUAL MEETING

Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting

On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.

2025 Clinical Summer School

NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders

On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.

2026 Neuromuscular Postdoc Research Fellowship Competition

2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!

Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)

Clinical Fellowship Awardees

Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients

We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.